Loading
Anxiety Disorders / Pharmacotherapy / Psychotherapy · Journal article
Dialogues in Clinical Neuroscience · August 25, 2026
Encouraging direction, but not yet definitive.
This ALE meta-analysis of 27 fMRI studies suggests that psychotherapy and pharmacotherapy engage partly distinct neural pathways in anxiety disorders: psychotherapy associates with broader decreases in prefrontal and striatal regions, whereas pharmacotherapy shows more focal decreases in the right uncus. The authors explicitly characterize findings as exploratory due to limited and heterogeneous evidence, and clinical symptom reduction data derive from a subset of only 9 cohorts.
Activation Likelihood Estimation meta-analysis of task-based fMRI studies. Task-based fMRI studies reporting pre- and post-treatment coordinates in patients with anxiety disorders (panic disorder, social anxiety disorder, specific phobia); setting not specified.. Intervention: Psychotherapy (including CBT, MBSR, psychodynamic, interpersonal therapy) or pharmacotherapy (SSRIs, SNRIs, oxytocin).. Compared with: Psychotherapy versus pharmacotherapy for neural circuit modulation in anxiety disorders.. n = 561.
27 studies involving 561 patients included in ALE meta-analysis Psychotherapy associated with decreased activation in medial, middle, and inferior frontal gyri and caudate nucleus Pharmacotherapy showed more focal decreases in right uncus
Pharmacotherapy showed more focal decreases in right uncus
Clinicians should recognize that psychotherapy and pharmacotherapy may work through distinct neural mechanisms in anxiety disorders, though this remains preliminary. The exploratory nature of findings and substantial heterogeneity across studies limit definitive clinical recommendations at present.
Meta-analysis of 27 fMRI studies with 561 patients showing differential neural mechanisms between psychotherapy and pharmacotherapy in anxiety disorders, but findings are explicitly described as exploratory due to limited and heterogeneous evidence base.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that psychotherapy and pharmacotherapy may work through distinct neural mechanisms in anxiety disorders, though this remains preliminary. The exploratory nature of findings and substantial heterogeneity across studies limit definitive clinical recommendations at present.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Anxiety disorders (ADs) involve dysregulation of prefrontal-limbic circuits, but the neural effects of psychotherapy and pharmacotherapy remain unclear.Methods. We conducted an activation likelihood estimation (ALE) meta-analysis of task-based fMRI studies reporting pre- and post-treatment whole-brain coordinates in ADs. Separate analyses were performed for psychotherapy and pharmacotherapy. A random-effects synthesis assessed changes in primary anxiety symptoms where extractable data were available.Results. 27 studies involving 561 patients were included. Psychotherapy was associated mainly with decreased activation in prefrontal and striatal regions, including the medial, middle, and inferior frontal gyri and caudate nucleus, whereas pharmacotherapy showed more focal decreases in the right uncus. Subgroup analyses suggested heterogeneity across therapies, diagnoses, and tasks. 9 independent active-treatment cohorts (179 participants) showed a large pooled symptom reduction (Hedges' g = 1.44, 95% CI 0.99-1.90; I² = 75.1%).Conclusions. Psychotherapy and pharmacotherapy may engage partly distinct neural pathways in ADs, with broader prefrontal-striatal modulation after psychotherapy and more focal limbic effects after pharmacotherapy. Findings remain exploratory given the limited and heterogeneous evidence base.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.